Article Figures & Data
Additional Files
Data Supplement
- Supplemental Data -
Supplementary Figure 1 - Observed and predicted values of in vivo CLint,sec (a-b), CLsec,plasma (c-d) or CLr,plasma (e-f)
when using the RAF and REF approaches and different PSF than that used in Fig. 2.Supplemental Table 1 - LC-MS/MS parameters of peptides selected for targeted analysis of drug transporters in HEK293 cells and kidney tissue.
Supplemental Table 2 - Transporter protein abundance (pmol/mg membrane protein) in membrane samples extracted from OAT-expressing HEK293 cells and human kidney cortex.
Supplemental Table 3 - Observed and Predicted Values of CLint,sec,in vivo, CLsec,plasma, and CLr,plasma (mL/min/kg)
for REF and RAF approaches when passive diffusion secretory CL was assumed to be negligible.Supplemental Table 4 - : Observed and Predicted Values of CLint,sec,in vivo, CLsec,plasma, and CLr,plasma (mL/min/kg) for both REF and RAF approaches when passive diffusion secretory CL was included in the predictions.
Supplemental Figure 2 - After including passive diffusion secretory clearance when predicting CLint,sec,in vivo, both the REF and RAF approaches were equally as precise (RMSE) and unbiased (ME) in predicting the in vivo CLint,sec (a, b) as the predictions with only active uptake clearance as demonstrated by the overlapping 95% confidence intervals (lines).
- Supplemental Data -